Analysts Set Integra LifeSciences Holdings Co. (NASDAQ:IART) Target Price at $23.00

Integra LifeSciences Holdings Co. (NASDAQ:IART) has earned a consensus rating of “Reduce” from the eight research firms that are covering the company, MarketBeat reports. Three analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and one has given a buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $23.00.

A number of analysts have recently weighed in on IART shares. Citigroup increased their price objective on Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a research note on Tuesday, November 5th. BTIG Research raised shares of Integra LifeSciences from a “sell” rating to a “neutral” rating in a research report on Monday, October 7th. Morgan Stanley assumed coverage on shares of Integra LifeSciences in a research report on Monday, December 2nd. They issued an “underweight” rating and a $20.00 price objective on the stock. Bank of America dropped their target price on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a report on Monday, October 7th. Finally, Truist Financial reduced their price target on Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a report on Monday, October 14th.

Insiders Place Their Bets

In other news, EVP Michael J. Mcbreen sold 1,700 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $24.16, for a total transaction of $41,072.00. Following the sale, the executive vice president now owns 56,182 shares in the company, valued at approximately $1,357,357.12. The trade was a 2.94 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 3.10% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. KBC Group NV grew its holdings in Integra LifeSciences by 65.2% in the third quarter. KBC Group NV now owns 2,839 shares of the life sciences company’s stock worth $52,000 after purchasing an additional 1,120 shares during the period. Northwest Investment Counselors LLC bought a new stake in shares of Integra LifeSciences in the 3rd quarter worth approximately $73,000. Canada Pension Plan Investment Board purchased a new stake in shares of Integra LifeSciences in the 2nd quarter worth approximately $114,000. Allspring Global Investments Holdings LLC increased its position in Integra LifeSciences by 58.0% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 4,662 shares of the life sciences company’s stock valued at $136,000 after buying an additional 1,711 shares in the last quarter. Finally, Centiva Capital LP purchased a new position in Integra LifeSciences during the third quarter valued at $192,000. 84.78% of the stock is owned by hedge funds and other institutional investors.

Integra LifeSciences Price Performance

Shares of NASDAQ:IART opened at $23.17 on Wednesday. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. The stock has a market cap of $1.79 billion, a PE ratio of -257.42, a PEG ratio of 0.82 and a beta of 1.15. The company’s fifty day moving average is $23.17 and its 200 day moving average is $22.88. Integra LifeSciences has a 52 week low of $16.81 and a 52 week high of $45.42.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Monday, November 4th. The life sciences company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.39 by $0.02. The firm had revenue of $380.80 million for the quarter, compared to the consensus estimate of $375.81 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The company’s quarterly revenue was down .4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.76 earnings per share. Research analysts anticipate that Integra LifeSciences will post 2.45 earnings per share for the current year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.